Dr. Paul Shami is a Professor of Medicine in the Division of Hematology and Hematologic Malignancies at the University of Utah and a Member and Clinical Investigator at the University’s Huntsman Cancer Institute. He is an Adjunct Professor in the Department of Pharmaceutics and Pharmaceutical Chemistry. He graduated with a Bachelor of Science in Chemistry and a Doctor of Medicine degrees from the American University of Beirut. He pursued his residency training in Internal Medicine and a fellowship in Hematology/Oncology at Duke University in Durham, North Carolina. He trained in the laboratory of Dr. J. Brice Weinberg at Duke. After 3 years on the Faculty at Duke he joined the University of Utah School of Medicine in 1997. He is Board Certified in Hematology and Medical Oncology. He is a member of the Acute Myeloid Leukemia and Myelodysplastic Syndromes panels of the National Cancer Center Network. Dr. Shami’s laboratory and clinical research efforts focus on the development of new therapies for hematologic malignancies. With Dr. Larry Keefer’s group at the NCI he has developed arylated dizeniumdiolates for the treatment of malignant diseases. A lead compound of this class (JS-K) is now in pre-clinical development. He has co-founded JSK Therapeutics and Lone Star Thiotherapies, two start-up biotechnology companies in order to lead the development of different anti-cancer technologies.